AngioDynamics ( (ANGO) ) has shared an announcement.
AngioDynamics reported its fiscal third quarter 2025 results, highlighting a 9.2% increase in net sales to $72.0 million, driven by a 22.2% growth in MedTech sales. The company achieved a GAAP gross margin of 54.0% and improved its adjusted EBITDA to $1.3 million, reflecting strategic focus on MedTech markets. Key developments include FDA clearance for the NanoKnife System for prostate tissue ablation and the initiation of the AMBITION BTK trial for the Auryon Atherectomy System. AngioDynamics also secured a $25 million revolving line of credit from J.P. Morgan, enhancing financial flexibility.
More about AngioDynamics
AngioDynamics, Inc. is a leading medical technology company focused on restoring healthy blood flow in the vascular system, expanding cancer treatment options, and improving quality of life for patients. The company operates primarily in the MedTech industry, with a strong emphasis on innovative technologies such as the Auryon Atherectomy System, AngioVac and AlphaVac thrombectomy systems, and the NanoKnife irreversible electroporation platform.
YTD Price Performance: 7.57%
Average Trading Volume: 695,931
Technical Sentiment Signal: Sell
Current Market Cap: $380M
Find detailed analytics on ANGO stock on TipRanks’ Stock Analysis page.